pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
Endpoints·Jul 1·1 min read
save

Biotech funding surge: 40 companies secure $100M+ rounds in H1 2026

Jul 1, 2026·read at Endpoints ↗DealPositive

Endpoints News reported that 40 private biotech firms announced funding rounds of at least $100 million each in the first half of 2026.

This count surpasses the number recorded for the same period in 2025, indicating a notable uptick in large-scale financing for the sector.

The surge, highlighted by a strong June, suggests continued investor appetite for biotech ventures as they advance pipelines and development programs.

source

This writeup was produced by pharmadog from original reporting by Endpoints.

Original headline: “A June flourish lifts biotech megaround tally in first half of 2026”

read at Endpoints ↗
83 words · retrieved Jul 1
sharex / twitterlinkedin

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?

companies & drugs in this story

topics
Private Biotech2

related stories

  • Aug 10Jazz to buy rare epilepsy drugmaker in potentially $1.3B dealBioPharma Dive
  • Jul 6Gene editing developer Scribe plots an IPOBioPharma Dive
  • Jul 6Cancer, immune drugmakers dominate VC funding so far in 2026BioPharma Dive
  • Jul 1STAT+: FDA approves Orca Bio’s T cell therapy for blood cancer patientsSTAT
  • Jun 30Nominations are open for the 2026 Endpoints 11 awardsEndpoints